Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

NEXT STORY
Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update
PREV STORY
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting

author_avatar
NASDAQ Market News

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in November

author_avatar
NASDAQ Market News

Global Companion Diagnostics Market to Witness a CAGR of 19% During 2019-2025

author_avatar
NASDAQ Market News